Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
Enanta Pharmaceuticals reports 2020 executive compensation
By ExecPay News
Published: January 21, 2021
Enanta Pharmaceuticals reported fiscal year 2020 executive compensation information on January 21, 2021.
In 2020, five executives at Enanta Pharmaceuticals received on average a compensation package of $2.5M, a 16% increase compared to previous year.
Average pay of disclosed executives at Enanta Pharmaceuticals
Jay R. Luly, Chief Executive Officer, received $5.2M in total, which increased by 16% compared to 2019. 69% of Luly's compensation, or $3.6M, was in option awards. Luly also received $416K in non-equity incentive plan, $667K in salary, $497K in stock awards, as well as $19K in other compensation.
For fiscal year 2020, the median employee pay was $232,629 at Enanta Pharmaceuticals. Therefore, the ratio of Jay R. Luly's pay to the median employee pay was 22 to one.
Yat Sun Or, Chief Scientific Officer, received a compensation package of $1.8M, which increased by 13% compared to previous year. 53% of the compensation package, or $982K, was in option awards.
Nathalie Adda, Chief Medical Officer, earned $1.8M in 2020, a 12% increase compared to previous year.
Nathaniel S. Gardiner, General Counsel, received $1.8M in 2020, which increases by 20% compared to 2019.
Paul J. Mellett, Chief Financial Officer, earned $1.8M in 2020, a 16% increase compared to previous year.
Enanta Pharmaceuticals' fiscal year ends on September 30.
Related executives
You may also like
Source: SEC filing on January 21, 2021.